Cash Flow Statement (Annual)

ENV / Envestnet, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss - - - - - 13,979 4,436 -55,567 -3,280
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 4,499 5,703 6,376 12,400 15,329 18,651 27,962 63,999 62,820
    Increase Decrease In Deferred Charges - - - - - -275 -1,819 438 -1,027
    Provision For Doubtful Accounts 385 2,668 - - 203 15 176 1,122 867
    Deferred Income Taxes And Tax Credits 1,572 1,215 2,162 83 -2,546 -4,640 -10,508 5,584 -4,597
    Share Based Compensation 780 1,731 3,062 4,342 8,738 11,423 15,161 33,276 31,331
    Interest Expense Debt - - - - - 626 10,271 8,244 8,994
    Accretion Expense - - 786 3 787 1,472 888 150 512
    Payment For Contingent Consideration Liability Operating Activities - - - - - - - - -
    Income Loss From Equity Method Investments - - - - - - - -1,420 -1,469
    Gain Loss On Disposition Of Assets - - - - - - - -398 -76
    Increase Decrease In Operating Assets
      Increase Decrease In Accounts Receivable 1,338 3,718 -1,940 -1,017 9,566 -1,788 9,297 -1,646 8,121
      Increase Decrease In Prepaid Deferred Expense And Other Assets 148 599 1,988 -4,645 1,075 -9,733 -14,716 3,290 787
      Increase Decrease In Other Noncurrent Assets -42 52 1,006 188 1,444 873 6,025 98 1,690
      Increase Decrease In Accrued Liabilities 38 2,437 802 3,100 12,389 9,784 -13,653 17,174 16,810
      Increase Decrease In Accounts Payable -475 -185 267 640 2,914 -659 3,128 -462 -442
      Increase Decrease In Deferred Revenue -187 208 -507 1,028 1,625 4,677 10,906 2,014 1,191
      Increase Decrease In Other Operating Liabilities 68 137 -39 1,166 1,074 26 -3,792 3,776 2,427
  Net Cash Provided By Used In Operating Activities 8,365 1,467 24,721 28,541 - - 42,035 81,270 108,607
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 3,078 4,169 4,798 4,838 6,125 6,177 9,184 13,967 14,945
  Payments To Develop Software 1,306 1,340 1,482 2,350 3,143 3,382 5,532 8,609 12,624
  Payments To Acquire Businesses Net Of Cash Acquired - 917 23,719 62,352 8,992 59,570 328,305 31,613 -
  Net Cash Provided By Used In Investing Activities -5,040 -5,501 -30,133 -69,707 - - -344,621 -57,927 -29,019
Net Cash Provided By Used In Financing Activities
  Proceeds From Long Term Lines Of Credit - - - - - 30,000 10,000 40,000 35,000
  Repayments Of Long Term Lines Of Credit - - - - - 30,000 10,000 40,000 62,500
  Payment For Contingent Consideration Liability Financing Activities - - - - - 6,000 7,219 3,729 2,286
  Payments To Acquire Businesses Gross - - - - - - - - 445
  Repayments Of Secured Debt - - - - - - 10,000 8,000 35,862
  Proceeds From Stock Options Exercised 3 1,925 2,747 2,069 6,400 5,190 8,279 4,924 7,951
  Payments Related To Tax Withholding For Share Based Compensation - - - - 622 2,062 7,412 10,966 13,974
  Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans - - - 2,759 1 1 2 6 5
  Net Cash Provided By Used In Financing Activities -245 40,177 2,653 6,240 - - 144,550 -22,469 -72,440
Effect Of Exchange Rate On Cash And Cash Equivalents - - - - - - - - 375
Cash And Cash Equivalents Period Increase Decrease 3,080 36,143 -2,759 -34,926 - - -158,036 874 7,523
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -
Income Taxes Paid Net 240 171 813 796 4,708 2,131 1,700 1,114 3,261
Interest Paid Net - - - - - - 3,877 8,356 7,353
Supplemental Cash Flow Information
  Purchase Liabilities Included In Accrued Expenses Not Yet Paid - - - - - - 13,676 996 856
  Accrued Payment To Fund Deferred Compensation Liability Included In Accounts Payable - - - - - - - - -
  Capital Expenditures Incurred But Not Yet Paid - - - - - 158 - 1,136 1,286

Peers - Business Services, Not Elsewhere Classified (7389)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 29404K106